YP
TVTX icon

YANKCOM Partnership’s Travere Therapeutics TVTX Stock Holding History

YANKCOM Partnership’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$2.97K – 379
2026
Q1 		$2.97K Hold
100
– – ﹤0.01% 321
2025
Q4 		$3.82K Buy
+100
New +$3.25K ﹤0.01% 321

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

YANKCOM Partnership's TVTX Position: Q2 2026 in Review

YANKCOM Partnership sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 100 shares — an estimated $2.97K sold.

YANKCOM Partnership first reported a position in TVTX in Q4 2025 and held it in 2 quarters. The position peaked at $3.82K in Q4 2025. 106 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • YANKCOM Partnership reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
  • YANKCOM Partnership sold 100 Travere Therapeutics shares in Q2 2026, an estimated $2.97K.
  • YANKCOM Partnership first reported a position in Travere Therapeutics in Q4 2025 and held it in 2 quarters.
  • YANKCOM Partnership's Travere Therapeutics position peaked at $3.82K in Q4 2025.
  • 106 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on YANKCOM Partnership's 13F filing for Q2 2026, filed 21 Jul 2026.